Pharminent

Novartis explains why it canned the cell therapy unit

The Swiss pharma talked about its reasons for re-absorbing its Cell & Gene Therapies unit during a call with investors.  http://www.biopharmadive.com/news/novartis-explains-why-it-canned-the-cell-therapy-unit/429024/

Filed under: Company